NCT Number: NCT00865033
A Relative Bioavailability Study of Metformin HCL Tablets, 1000 mg Under Fasting Conditions
The purpose of this study is to demonstrate the relative bioequivalence of Metformin HCL Tablets, 1000 mg under fasting conditions.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 1
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.
Exclusion criteria
- Positive test results for HIV or hepatitis B or C.
- Treatment for drug or alcohol dependence.
Treatment and study plan
Glucophage 1000 mg
DrugPrimary outcomes
-
Bioequivalence according to US FDA guidelines
Time frame: 9 days
Sponsors and collaborators
Lead sponsor
Sandoz
Industry
Registry information
Official study title
A Relative Bioavailability Study of Metformin HCL 1000 mg Tablets Under Fasting Conditions
Important dates
- Study start
- 2005
- Primary completion
- 2005
- Study completion
- 2005
- First posted
- Mar 19, 2009
- Registry last updated
- Mar 29, 2017
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
NCT05929079
Apnea, Body Weight
Anniston, Alabama, United States
View Trial DetailsA Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes
NCT06649344
Diabetes Mellitus, Diabetes Mellitus, Type 2
Tianjin, Tianjin Municipality, China
View Trial DetailsEfficacy of Once Weekly Semaglutide in Patients With Type 2 Diabetes: a Non Randomized Clinical Trial
NCT07732218
Diabetes Mellitus, Diabetes Mellitus, Type 2
Peshawar, Khyber Pakhtunkhwa, Pakistan
View Trial DetailsmHealth Intervention to Increase Physical Activity in Prediabetes and Type 2 Diabetes
NCT05351359
Diabetes Mellitus, Diabetes Mellitus, Type 2
Prague, Czechia
View Trial Details